'Golden age' of weight loss jabs coming – some are about to get a lot cheaper
Scientists herald 150 new jabs and pills to tackle obesity going through the research pipeline - but issue urgent warning to the NHS
A 'golden age' of weight loss drugs is on the horizon which could finally reverse the rising tide of obesity, scientists say. The leader of the first head-to-head trial comparing the two leading appetite-suppressing jabs revealed at the European Obesity Congress in Malaga, Spain, there are 150 more such drugs in the pipeline.
A host of obesity experts have called on the NHS to urgently ramp up capacity at its weight loss clinics so pills and jabs can be cheaply prescribed to much of the population as they come 'off patent'. Professor Jason Halford, of the European Association for the Study of Obesity, said: 'If the government and NHS are serious about prevention they need to reconsider their position on the speed of the rollout of these drugs, as this evidence comes to light.
"In ten years time the landscape is going to be completely different. There will be lots more obesity drugs available, they should be in more usable forms and they should be a lot more affordable.'
Dr Louis Aronne, director at Weill Cornell Medicine, New York, US, led a trial showing the Mounjaro jab saw users lose 50% more weight than Wegovy, and that newer versions would keep getting better. He said: 'I think we're going to see more medications. The other day I saw a list of 150 medications, many GLP-1s, but also other mechanisms. I call it the golden age of obesity treatment.'
'They will be less expensive, and hopefully the oral small molecules which are cheaper to manufacture and distribute. I think health systems should be ready to roll them out at scale.'
Obesity rates have been rising globally for the last 30 years and more than a billion people are now considered obese. This has contributed to a rising tide of chronic illness, particularly in the West, where we live longer with diseases such as cancer, heart disease, dementia and diabetes placing a huge burden on healthcare systems.
Pharmaceutical companies are pumping tens of billions of pounds into a new generation of appetite-suppressing medicines which could finally help reverse the rise in obesity. Weight loss pills are expected to take over from injections making them more readily available.
Prof Halford added: 'The Holy Grail would be the small molecule, something that works as a hormone would do. But we could take orally like a regular tablet and that's where I think we will be going in probably the next 10 years. In a decade from now we'll have some of the medications off license so they'll be much cheaper. The more treatment we have, the more competition we have, the lower the prices. At the moment the NHS rollout does not take into account the number of medications potentially available in the next 10 years.'
Novo Nordisk manufactures market leading jabs Wegovy and Ozempic, for type 2 diabetes which are both due to come 'off patent' in the coming years so generic versions will be sold for a few pence rather than hundreds of pounds. It also has a pill form of the drugs going through clinical trials.
Another study presented at the conference showed Wegovy halved the risk of dying from stroke or heart attack in people with obesity and cardiovascular disease. The Select trial also found Wegovy protected against heart disease even before people had lost any weight, possibly by reducing inflammation.
Author Professor Donna Ryan, presenting the findings from manufacturer Novo Nordisk, said they "should change public policy everywhere". She added: "I think what our study today does is it further emphasises there is no need to wait. There's always inertia in medicine. We're slow moving. What this analysis says is that this treatment works early - so why wait?'
Currently around half a million Brits are taking the weekly jabs, mainly by paying for private prescriptions, despite over four million being eligible for them on the NHS.
NHS England responded justifying its gradual rollout of jabs such as Mounjaro, which will only see 220,000 people being prescribed it in the next three years due to the cost and resources needed to provide accompanying weight management support from a specialist.
Dr Claire Fuller, NHS England's medical director for primary care, said: 'Weight loss drugs are a powerful part of our arsenal to tackle obesity and support people to lose weight and reduce their risk of other illnesses like diabetes, heart attacks and stroke. From next month, some eligible patients will be able to access the weight loss drug Mounjaro for the first time. The drug has already been approved for use for some adults in specialist weight management services, and 220,000 people will be eligible to benefit over the first three years.
'This phased roll out will ensure those with the greatest clinical need can access the treatment as a priority, at the same time as the NHS develops new and innovative services through which other weight loss treatments can also be delivered in the future. Local NHS organisations will be providing further information on how patients can access services in due course.'
The powerful drugs must be prescribed alongside specialist support to help people transform their diet and activity levels. Without substantial lifestyle changes users will pile the weight back on if they ever come off the jabs. Some people have to stop taking them due to side effects, such as vomiting.
Novo Nordisk patented its blockbuster GLP-1 drug semaglutide in both its branded forms Ozempic and Wegovy. Its 'core' patient expires in 2026 but the pharmaceutical company has 220 'secondary' patients in 28 countries which could extend its market exclusivity to 2033. After then the price of drugs based on its semaglutide molecule will plummet and the availability of generic versions of the drugs will explode.
Other first-generation weight loss jabs such as liraglutide, sold under the brand names Saxenda for obesity and Victoza for diabetes, and dulaglutide, brand name Trulicity, are set to see their patents expire soon paving the way for generic alternatives.
Dr Sonya Babu-Narayan, director at the British Heart Foundation, said: 'A generation ago, effective drugs for obesity would have been a pipe dream. Yet here we are with the potential to make a massive dent in the number of lives cut too short by cardiovascular disease and other conditions such as dementia and cancer. It is imperative that the health service embraces this opportunity and ensures those in need of these lifesaving treatments can access them.'
Big pharma is competing to find new drugs including one drug dubbed the 'Godzilla' of appetite-suppressing injectables which saw trial participants lose up to 24% of their body weight in less than a year. The weekly jab called retatrutide helps the body burn more fat as well as making users feel more full so they eat less. This twin approach has helped it outperform Wegovy, Ozempic and Mounjaro which only suppress appetite.
As well as GLP-1 and GIP hormones, retatrutide targets a third hormone known as glucagon which triggers the body to burn more fat when we move. The trial results showed it helped people with obesity shed 60 pounds on average in just 48 weeks. Women lost even more shedding 28.5% of their body weight compared to 21.2% in the male half of the trial.
But experts insist these drug breakthroughs should not stop political leaders from ignoring the root causes of obesity, namely that society is now set up so we usually have cheap, unhealthy food at our finger tips and it is difficult or expensive to make the healthy choice.
Katharine Jenner, director of the Obesity Health Alliance, said: 'It's no surprise that major pharmaceutical companies are investing heavily in obesity treatment. They recognise the scale of the opportunity. That opportunity exists largely because we've failed to tackle the root causes of obesity.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
23 minutes ago
- BBC News
Inflatable pillow trialled to help reposition critically-ill patients
An innovative inflatable pillow is being trialled to help move and reposition patients in intensive care faster and in a safer pillow is placed under a critically-ill patient, who may be sedated or ventilated, and is slowly inflated in sections to lift their chest and hip, helping ward staff safely reposition device, which is being trialled at Royal United Hospitals (RUH) in Bath, was co-developed by its clinicians and a team of researchers from the University of Bath."Moving critically-ill patients is a significant challenge on intensive care wards worldwide," said Dr Alexander Lunt, senior lecturer in mechanical engineering at the University of Bath. Clinical trials using the Inflatable Prone Repositioning Device - known as 'BathMat' - began in late trials are backed by a 14-month funding award from the National Institute for Health and Care Research. Further trials will involve 30 patients from four NHS intensive care units, including Southmead Hospital in North Bristol, Wythenshawe Hospital in Manchester and Derriford Hospital in assistance provided by the BathMat has the added benefit of reducing the number of staff needed to move a patient from five to key outcomes experts will measure will include reductions in staff time required to reposition patients and reduction of pressure injuries, like Jerome Condry, chief investigator and research fellow at Royal United Hospitals Bath, said that other ICU teams were showing enthusiasm for the device."Teams recognise the potential our device has to making repositioning proned (face-down) patients easier and safer for everyone involved," he said."We've already had other trusts reach out asking how they can access the device."
BBC News
27 minutes ago
- BBC News
Police launch investigation into heart operation deaths at NHS hospital
Police have launched an investigation into the deaths of patients following heart operations at an NHS hospital, the BBC has seen by us suggest patients suffered avoidable harm - and that in some cases their death certificates failed to disclose that the procedure contributed to their woman's operation at Castle Hill Hospital near Hull - that should have taken no more than two hours - has been described as a "disaster" by one spent six hours in surgery and lost five litres of blood - all while under local none of this was mentioned on her death certificate, which recorded her as dying from pneumonia. Her family were also not told what had NHS body that runs Castle Hill, the Humber Health Care Partnership, told the BBC it had delivered improvements suggested by the Royal College of Physicians (RCP). In a statement, it said it was happy to directly answer any questions from the patients' Police said an investigation was "in the very early stages" and no arrests had been made. 'Very concerned about safety' The documents raise concerns about the care that 11 patients received during a TAVI - Transcatheter Aortic Valve Implant - a procedure to replace a damaged valve in the heart, similar to adding a department's TAVI mortality rate at the time was three times higher than the UK average, something patients and families were also unaware concerns within the hospital led managers to commission several reviews - but none was made public. In 2020, the RCP was asked to assess the whole cardiology department, in which the TAVI team was operating, including two of the TAVI report, completed in 2021, led to a second review conducted by consultants IQ4U, which recommended a third review of all 11 deaths, which was also conducted by the Royal College and completed in early BBC has been passed copies of all three inquiries. The patients' families only found out they had taken place when we contacted in 2021, seven cardiac consultants wrote they were "very concerned about the safety and transparency of the TAVI service" in a letter to the hospital's chief executive. It followed the deaths, in less than six months, of four of the 11 patients. Used instead of open-heart surgery, the TAVI procedure involves inserting a new valve via a catheter through a blood vessel, often in the groin. The catheter guides the new valve to the heart and replaces the damaged procedure, which typically lasts between one and two hours, is usually carried out under local anaesthetic and is mainly performed on older Readhead, from Driffield, went to Castle Hill to undergo a TAVI in summer 2020. The 87-year-old, an active member of her local church and a keen gardener, had been suffering bouts of breathlessness which doctors had blamed on a heart not suitable for open-heart surgery, Mrs Readhead was keen to take up the option of the less-invasive procedure. "She thought it would give her a [better] quality of life," says her daughter, Christine the operation went care Mrs Readhead received formed part of both RCP reviews carried out on behalf of the hospital trust. Pre-op checks had indicated Mrs Readhead's left side was to be used for the TAVI, as her right side had some blockages because of calcified manufacturer of the TAVI device that was to be implanted had also written a technical report clearly stating that access via the patient's right artery was the day of the operation however, the TAVI medics went in through Mrs Readhead's right leg by mistake. Realising their error, they paused to consider their options but decided to continue - despite the procedure being an elective rather than an emergency attempted to deploy the TAVI three repeated efforts resulted in a significant tear in Mrs Readhead's femoral artery, a major blood vessel. By now, she had been on the surgical table for six hours, lost five litres of blood, and had been awake throughout. Mrs Readhead's care was "graded poor" by the RCP in its 2021 report. It concluded this because of the use of an "inappropriate access site" during a procedure, stating this "unfortunately resulted in an avoidable vascular complication".The TAVI team's decisions "resulted in a disaster for this patient", an anaesthetist called in to rescue the situation wrote two days after the operation in an email - seen by the described it as "a change of plan without weighing the risks vs benefit for the patient, but having a 'have a go' approach".Dr Thanjavur Bragadeesh, then-clinical director of the cardiac unit, suggested the case should be declared a serious incident (SI) when he was made aware of it a few days later. This would mean a full investigation by the hospital. But this suggestion was initially rejected by the vascular surgeon who had been part of the TAVI team."These were recognised complications which were anticipated as of significant risk... The aim of the [forthcoming] meeting is to celebrate and reinforce what went well," he wrote in an head of the TAVI team, agreed, replying it was "an unfortunate but well recognised complication".The hospital did, however, investigate Mrs Readhead's case as a serious incident. While it noted that her death, a week after the operation, provided areas for learning, "these would not have prevented the incident from occurring". It concluded the team had "worked collaboratively and well together".This conclusion was shared with Mrs Readhead's family, with no mention of the TAVI manufacturer's warning or the failure to deploy the device on three attempts. Mrs Readhead's death certificate also makes no mention of the cause of death is listed as "hospital-acquired pneumonia and severe aortic stenosis" - the condition the hospital had been attempting to the second RCP review in 2024 strongly disagreed with the death certificate wording."The vascular injury during the TAVI procedure should have been detailed, as this led to the patient's death," it Readhead's daughter says she had no idea what her mother had endured until the BBC showed her the documentation."None of that was told to us. None of it," says Christine Rymer. "It just feels as if mum was a guinea pig, which is not nice to think about."The 2024 review looked at the deaths of 11 patients in total - seven women and four men who all had TAVI procedures, including Mrs Readhead. Ten deaths occurred between October 2019 and March 2022 - the other happened in May 2023. The review's findings included:"Poor clinical decision-making" at every stage of the treatment of a male patient, aged 73 - including incorrect positioning of the TAVI valveThe same patient's final death certificate failing to contain an "an accurate description" of what happened. He was issued with two certificates - the first one mentioning a "failed TAVI" was withdrawn, while a second one weeks later stated he died from pneumonia and didn't mention the TAVICriticism of death certificates issued to two other patients, both women who died within six weeks of each other, saying crucial details were missing, making them inaccurateNo mitigation for a female patient, aged 84, who had an "elevated risk" - which led to a complication "that might have been avoided under more experienced operators" The BBC has also seen the 2021 letter from the "very concerned" cardiac consultants to the hospital's chief executive, Chris Long, and chief medical officer, Dr Purva one death that year, the consultants said they had been "alarmed to read" that the coroner had not been informed of a serious complication during the operation, with the cause of death recorded as a heart Bragadeesh, who was one of the signatories, says he believes the TAVI service at Castle Hill should have been suspended at that time because the mortality rate was so high compared to most other UK hospitals. Former fisherman Brian Hunter, from Grimsby, was another of the 11 patients who died. He had faith in the NHS, say his family, although rarely visited a lived by the maxim that "a hot curry or a paracetamol" would cure all ailments - and "if that didn't work you, you just got on with it," according to his daughter, Tracy diagnosis of a heart problem therefore, at the age of 83, shocked his four daughters. But they and Brian were reassured a TAVI procedure would soon allow him to resume his gardening and cooking his Sunday there was "a lack of urgency" to treat him, according to the 2024 RCP review - and by the time he underwent the operation, in October 2021, he was "a high-risk case… with an increased risk of complication and little margin for error". The TAVI team had made technical errors, concluded the review, failing to properly deploy the device which then wrongly allowed blood to leak back into the Hunter didn't survive the operation - the Royal College graded his care as "very poor". His daughters - just like Dorothy Readhead's family - had no idea what had happened during his operation until we showed them the report."We were led to believe that dad had a heart attack on the table and unfortunately passed away," said Mrs Fisher. "To find out three years down the line that what your father actually passed from wasn't the truth is torturous."I feel angry as well, and so does the rest of the family, that [the hospital] just outrageously lied. At no point do any of us find it acceptable. It's just not." After raising concerns about Mrs Readhead's case in 2020, Dr Bragadeesh was asked to step down from his role as clinical director of Castle Hill Hospital's cardiology department as part of a wider leadership the rationale for the reorganisation was challenged, the trust asked the RCP to conduct its 2021 review, including assessing whether the decision to change the management team and his role was were poor working relationships within the cardiology department, found the RCP at that time, with reviewers adding that they "positively acknowledge the decision to step down the cardiology leadership roles".Dr Bragadeesh continued to work at Castle Hill but took the trust to an employment December 2023, the tribunal dismissed three of his 29 complaints and said of the remaining 26 that they were out of time, concluding he should have brought his case now works at a different NHS trust. He says the failures identified in the 2024 Royal College of Physicians review "show I was right to raise concerns about the TAVI procedure".The Humber Health Care Partnership - which runs Castle Hill through Hull University Teaching Hospitals NHS Trust (HUTH) - said in a statement: "We understand families may have questions and we are happy to answer those directly."It said that following a 2021 review, the RCP concluded the TAVI service was essential for the region, but said the design of the service should be reviewed and invested in."The report offered a number of actions for improvement and we have delivered against all of those since it was shared with us," it said its services retained the confidence of the healthcare inspector, the Care Quality trust added that three separate external reviews had been undertaken "and shown that mortality rates associated with TAVI are similar to national mortality rates over a four-year period".The mortality data it shared with the BBC indicates that the unit remains above the UK national reporting by Tara Mewawalla
The Independent
2 hours ago
- The Independent
AI foot scanner could keep people with heart failure out of hospital
An in-home foot scanner that uses artificial intelligence (AI) to recognise the warning signs of heart failure could help keep people with the condition out of hospital, according to researchers. The device, which is roughly the size of a smart speaker, operates in a similar way to facial recognition by taking and analysing almost 2,000 pictures a minute to calculate the level of fluid in the feet and ankles. This water retention, known as oedema, is one of the three major warning signs that heart failure is becoming severe and potentially life threatening. The AI scanner is able to trigger an alert to healthcare professionals so they can take action, such as increasing their patient's medication. The Foot Study, which is being presented at the British Cardiovascular Society annual conference in Manchester, suggests these alerts come 13 days before a person would end up in hospital. It involved 26 heart failure patients from five NHS trusts who were enrolled between 2020 and 2022. They were monitored using the AI device and were also asked to weigh themselves using Bluetooth-enabled scales. Seven instance of worsening heart failure was detected in six patients, while one death from the condition was recorded. Researchers found that, in patients enrolled in the study for at least two weeks before an alert was triggered, the average lead time before hospital admission was 13 days. The lead time averaged eight days when all five triggers picked up by the device were analysed. The study also found that monitoring using the scales failed to predict any heart failure-related hospital admissions. Researchers suggested this is because patients struggled to stick to tracking their weight, whereas the AI device did not require any action. Dr Philip Keeling, senior author of the study and a consultant cardiologist at Torbay and South Devon NHS Foundation Trust, said: 'Only about half of people admitted to hospital with heart failure currently get assigned an early review by a heart failure nurse who can check to see if they are suffering a harmful build-up of fluid because their heart is not working properly. 'Amid a shortage of heart failure nurses, a device like this can be like a virtual nurse, tracking people's health.' The device, developed by Cambridge-based start-up Heartfelt Technologies, is mounted to the wall and is typically installed at a patient's bedside. It uses AI technology to detect a person's foot and lower leg and track their position, so a camera can take 1,800 pictures a minute from multiple angles. These images reveal the volume of fluid in the foot and lower leg. It works without wifi, and only scans the legs to a height of 50cm from the floor. Heart failure is a long-term condition that means the heart is unable to pump blood around the body properly, usually because the heart has become too weak or stiff. Is it estimated that more than a million people are living with heart failure in the UK. The three main symptoms that indicate the condition is getting worse are increased breathlessness, weight gain and swelling in the legs or ankles. Dr Keeling added: 'Living with heart failure can be overwhelming, with all the medications, medical tests and appointments, and the requirement to monitor your own health. 'This scanner, once it is installed, just automatically keeps an eye on you and alerts the heart failure nurse, which is a huge relief.' At the end of the study, 18 of the 22 surviving patients kept the AI device. Reacting to the findings, Professor Bryan Williams, chief scientific and medical officer at the British Heart Foundation (BHF), said: 'This small study suggests a simple device could significantly improve outcomes for at-risk patients with heart failure by keeping them out of hospital. 'This study is a good example of how technology might aid earlier interventions and treatment, by allowing people to track a key sign of their heart health at home. 'Innovations with the potential to transform heart care in this way are a major part of the BHF's goal to save and improve lives of people living with cardiovascular disease.'
